New Triple-Drug attack on advanced breast cancer enters final testing phase
Disease control
Recruiting now
This large, late-stage trial is testing whether adding an experimental drug called gedatolisib to two standard breast cancer medications works better than the standard two-drug combination alone. It's for people with advanced HR-positive, HER2-negative breast cancer that has wors…
Phase: PHASE3 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC